Psychiatry Research
Volume 179, Issue 2 , Pages 139-146, 30 September 2010

Effects of benzodiazepine treatment on cortical GABAA and muscarinic receptors: Studies in schizophrenia and rats

  • Mark C. McLeod

      Affiliations

    • The Rebecca L. Cooper Research Laboratories, The Mental Health Research Institute, Parkville, Australia
    • The Department of Psychiatry, The University of Melbourne, Victoria, Australia
  • ,
  • Elizabeth Scarr

      Affiliations

    • The Rebecca L. Cooper Research Laboratories, The Mental Health Research Institute, Parkville, Australia
    • The Centre for Neuroscience, The University of Melbourne, Victoria, Australia
  • ,
  • Brian Dean

      Affiliations

    • The Rebecca L. Cooper Research Laboratories, The Mental Health Research Institute, Parkville, Australia
    • The Department of Psychiatry, The University of Melbourne, Victoria, Australia
    • The Department of Psychological Medicine, Monash University, Clayton, Victoria, Australia
    • Corresponding Author InformationCorresponding author. The Rebecca L. Cooper Research Laboratories, The Mental Health Research Institute, Locked Bag 11, Parkville, Victoria, 3052, Australia. Tel.: +61 3 9389 2940; fax: +61 3 9387 5061.

Received 15 October 2008; received in revised form 24 March 2009; accepted 25 March 2009.

Abstract 

Changes in cortical γ-aminobutyric acid A (GABAA) receptors and muscarinic receptors have been reported in schizophrenia, a disorder treated with antipsychotic drugs and benzodiazepines. As there is a reported functional relationship between the GABAergic and cholinergic systems in the human central nervous system we have investigated whether there are changes in the GABAA and muscarinic receptors in the cortex of subjects from APD-treated subjects with schizophrenia and whether changes were different in subjects who had also received benzodiazepine treatment. We failed to show any strong correlations between changes in GABAA and muscarinic receptors in the CNS of subjects with schizophrenia. We showed that subjects with schizophrenia treated with benzodiazepines had lower levels of muscarinic receptors; which was not the case in rats treated with APDs, benzodiazepines or a combination of both drugs. Further, the benzodiazepine binding site, but not the muscimol binding site, was decreased in the parietal cortex of subjects with schizophrenia independent of benzodiazepine status at death. These data would therefore support our previously stated hypotheses that changes in the cortical cholinergic and GABAergic systems are involved in the pathophysiology of schizophrenia.

Keywords: GABAA receptor, Muscarinic receptor, APDs, Benzodiazepine, Cortex, Schizophrenia, Postmortem CNS

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0165-1781(09)00135-8

doi:10.1016/j.psychres.2009.03.034

Psychiatry Research
Volume 179, Issue 2 , Pages 139-146, 30 September 2010